Savara (SVRA)
Developing inhaled MOLBREEVI for autoimmune pulmonary alveolar proteinosis.
$5.50
Pre-market+0.04 (+0.73%)
At close$5.46(+2.06%)
Something off on this page? Send us feedback.
Next report
Nov 11, 2026
in 69 days
EPS estimate
−$0.16
Revenue estimate
$500.0K
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.13−$0.12−$0.14−$0.14−$0.13−$0.15−$0.16Pending
Estimate−$0.11−$0.12−$0.12−$0.13−$0.12−$0.14−$0.14−$0.16
Surprise−18.2%0.0%−16.7%−7.7%−8.3%−7.1%−13.3%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$272.0K——————Pending
Estimate—————$500.0K$2.0M$500.0K
Surprise————————
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.16 | — | — |
| Aug 2026 | −$0.14 | −$0.16 | −13.3% |
| May 2026 | −$0.14 | −$0.15 | −7.1% |
| Mar 2026 | −$0.12 | −$0.13 | −8.3% |
| Nov 2025 | −$0.13 | −$0.14 | −7.7% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Mar 2016 | |||
| Nov 2015 | |||
| Aug 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 11, 2026 | −$0.16 | — | — | $500.0K | — | — | — |
| Aug 11, 2026 | −$0.14 | −$0.16 | −13.3% | $2.0M | — | — | +2.3% |
| May 13, 2026 | −$0.14 | −$0.15 | −7.1% | $500.0K | — | — | 0.0% |
| Mar 13, 2026 | −$0.12 | −$0.13 | −8.3% | — | — | — | −0.4% |
| Nov 12, 2025 | −$0.13 | −$0.14 | −7.7% | — | — | — | +3.4% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||||||
| Aug 13, 2025 | |||||||
| May 13, 2025 | |||||||
| Mar 27, 2025 | |||||||
| Nov 12, 2024 | |||||||
| Aug 12, 2024 | |||||||
| May 9, 2024 | |||||||
| Mar 7, 2024 | |||||||
| Nov 9, 2023 | |||||||
| Aug 10, 2023 | |||||||
| May 15, 2023 | |||||||
| Mar 30, 2023 | |||||||
| Nov 10, 2022 | |||||||
| Aug 11, 2022 | |||||||
| May 11, 2022 | |||||||
| Mar 30, 2022 | |||||||
| Nov 12, 2021 | |||||||
| Aug 12, 2021 | |||||||
| May 13, 2021 | |||||||
| Mar 10, 2021 | |||||||
| Nov 5, 2020 | |||||||
| Aug 6, 2020 | |||||||
| May 7, 2020 | |||||||
| Mar 12, 2020 | |||||||
| Nov 7, 2019 | |||||||
| Aug 8, 2019 | |||||||
| May 9, 2019 | |||||||
| Mar 13, 2019 | |||||||
| Nov 7, 2018 | |||||||
| Aug 9, 2018 | |||||||
| May 9, 2018 | |||||||
| Mar 14, 2018 | |||||||
| Nov 8, 2017 | |||||||
| Aug 9, 2017 | |||||||
| May 9, 2017 | |||||||
| Mar 6, 2017 | |||||||
| Nov 8, 2016 | |||||||
| Aug 9, 2016 | |||||||
| May 6, 2016 | |||||||
| Mar 14, 2016 | |||||||
| Nov 12, 2015 | |||||||
| Aug 12, 2015 | |||||||